-
AI acquires SAL Science's expertise and cell growth supplements
Time of Update: 2022-09-08
Editor: Original Title: AI Acquires SAL Science’s Expertise and Cell Growth Supplements(Medicine News, August 3, 2022) Advanced Instruments ("AI"), a leading manufacturer of bioprocessing analytical instruments and services, announced the acquisition of SAL Scientific Ltd.
-
In the next 3-5 years, China's innovative pharmaceutical companies will usher in a big test! How to deal
Time of Update: 2022-09-06
" The industry said that with the increasing cost of innovative research and development and the low return on investment in the single market, the layout of pharmaceutical companies in the international market is a new way out, which is also conducive to enhancing the competitiveness of innovative enterprises.
-
AkzoNobel to acquire Lankwitzer Lackfabrik's liquid coatings business for aluminium wheels
Time of Update: 2022-08-17
Becoming a one-stop shop for the wheel industry by offering a comprehensive range of liquid and powder aluminum wheel coatings will significantly strengthen our position in the important automotive market ," explains Michael Friede, AkzoNobel's Chief Commercial Officer - Performance Coatings.
-
Ascend Engineered Polymers New Products to Debut at K 2019
Time of Update: 2022-08-17
Ascend Announces Its Growth Plan at K 2019 Preview Press Conference in Antwerp, Belgium Ascend Announces Its Growth Plan at K 2019 Preview Press Conference in Antwerp, Belgium As demand for functional materials continues to grow, the company is diversifying its product offerings by adding more specialty products, explained Scott Rook, Ascend's senior vice president of business .
-
AIDS Surgery Perioperative Antiviral Treatment, Meeting Minutes of Expert Consensus Exchange Meeting
Time of Update: 2022-01-09
Professor Liu Baochi, Professor Zhang Qiang of Beijing Ditan Hospital, Capital Medical University, shared the "Experts Consensus on Perioperative Antiviral Therapy for Patients with Human Immunodeficiency Virus Infected in China (Second Edition)".
-
Health Commission: 13 new confirmed cases, including 4 local cases
Time of Update: 2021-12-02
As of 24:00 on November 25, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 860 confirmed cases (including 8 severe cases), a total of 93,087 cured and discharged cases, and a total of 4,636 deaths.
-
The new energy "14th Five-Year Plan" is coming, and the instrument field has broad development prospects
Time of Update: 2021-11-27
【Chemical Machinery and Equipment Network Hot Concern ] Recently, in the proposal of the Communist Party of China * on formulating the 14th Five-Year Plan for National Economic and Social Development
-
Current status of product development of transdermal drug delivery preparations
Time of Update: 2021-09-19
Compared with traditional methods of administration, transdermal absorption preparations have the following advantages: they can produce durable, constant and controllable blood drug concentration, thereby reducing adverse reactions; avoiding the first pass effect of the liver and improving the bioavailability of the drug; The pain of injection medication; patients can take the medication by themselves, and the medication can be stopped in time if there is a problem, which is convenient to use .
-
Teresa is approved in China for adjuvant treatment of patients with early-stage EGFR-mutant lung cancer
Time of Update: 2021-07-09
" Dave Fredrickson, Global Executive Vice President of AstraZeneca and Head of Oncology Division, said: "The rapid approval of osimertinib in China is part of the curative treatment plan for early EGFR-mutant lung cancer, highlighting the considerable future in this field.
-
Optimize the mechanism and speed up the shuffling! The heroes are competing, look at the strategic direction of Tuqi in the second half of the year
Time of Update: 2021-05-01
Looking at the market competition in the second half of the year, each coating company keeps its own progress in focusing on R&D and product quality, and providing core competitiveness for high-quality development.
-
In February 2021, the world's first batch of 7 new drugs, the fourth CAR-T therapy Breyanzi was approved by the FDA
Time of Update: 2021-03-23
Author: SeaAccording to the global drug database of Yaodu, in February 2021, there were 7 new drugs approved for marketing for the first time in the world, all of which were approved by the FDA. Amon
-
Amber refracted ancient ecological conditions hundreds of millions of years ago
Time of Update: 2021-03-06
At the same time, the team analyzed sediments found in southeastern Australia, Tasmania and New Zealand, including amber from the oldest known pan-ancient continent 230 million years ago, rainforest deposits near Antarctica between 96 and 92 million years ago, and a complete felt python fossil between 54 million and 52 million years old.
-
Observation of the structure and function of plant roots
Time of Update: 2021-01-10
From the mature area of the root to make a horizontal cut or vertical, it is clear that the root's primary structure from the outside to the inside, respectively, the skin, cortical layer and tube column (Figure 5-1).
-
The United Arab Emirates has officially registered a new crown vaccine for China National Pharmaceutical Group
Time of Update: 2020-12-24
MEDICINE NETWORK, Dec. 10 (Xinhua) -- The Ministry of Health and Prevention of the United Arab Emirates announced On the 9th that it has officially registered a new crown inactivated vaccine developed by China National Pharmaceutical Group.
phase III clinical trials showed an 86 percent effective rate of the inactivated vaccine against new coronavirus infections, the statement said.
-
FDA adds Class II Device 510 (k) Waiver Review Channel modernization steps
Time of Update: 2020-08-08
under this law, the FDA generally does not require pre-market clinical evidence to support licensing of medical devices with a moderate risk level; , however, the 510 (k) channel requires the device manufacturer to certify that the device is "indeed equivalent" ("vally ally" in terms of intended use and technical characteristics (with the exception of permitted exceptions) to the device currently on the market (the "reference" device/predicate that has been listed).
